BIOASTER demonstrates Its know-how on generation, production and purification of nanoparticles.

Within recent years, the development of genetically engineered recombinant VLPs has accelerated the need for new, improved downstream processes. The technologic unit “Protein and expression system engineering” of Bioaster has set up a rapid low cost scalable purification process. The size-exclusion chromatography-based, scalable purification protocol was applied to the purification of a VLP-based influenza A vaccine produced in Escherichia coli. The study was published in March 2016 in Journal of Virological Methods*. The combination of this downstream strategy following production in Escherichia coli would be suited for production of VLP-based veterinary vaccines targeting livestock and companion animals where large amounts of doses must be produced at an affordable price.